
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Free Report) – Equities research analysts at Noble Financial issued their FY2026 earnings per share (EPS) estimates for Greenwich LifeSciences in a research note issued to investors on Wednesday, November 18th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of ($1.49) per share for the year. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.48) per share. Noble Financial also issued estimates for Greenwich LifeSciences’ Q4 2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.51) EPS, Q3 2027 earnings at ($0.55) EPS, Q4 2027 earnings at ($0.59) EPS and FY2027 earnings at ($2.14) EPS.
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.06).
View Our Latest Stock Analysis on GLSI
Greenwich LifeSciences Trading Down 1.6%
GLSI stock opened at $19.48 on Friday. The firm has a 50-day moving average of $16.87 and a two-hundred day moving average of $20.77. The firm has a market capitalization of $285.95 million, a PE ratio of 0.00 and a beta of 1.57. Greenwich LifeSciences has a one year low of $7.78 and a one year high of $34.10.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of GLSI. Ancora Advisors LLC raised its holdings in shares of Greenwich LifeSciences by 101.2% in the third quarter. Ancora Advisors LLC now owns 21,610 shares of the company’s stock valued at $390,000 after buying an additional 10,870 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Greenwich LifeSciences by 44.4% during the third quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company’s stock worth $1,025,000 after buying an additional 17,464 shares during the period. BlackRock Inc. acquired a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $11,398,000. Deutsche Bank AG acquired a new stake in Greenwich LifeSciences in the second quarter valued at $126,000. Finally, Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the 2nd quarter valued at about $1,124,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Greenwich LifeSciences
Here are a few of the latest stories about GLSI:
- Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target to $70. Article: Greenwich LifeSciences Stock Gets Price Target Boost from HC Wainwright
- Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including FY2026 from a loss of $1.29 to $1.46 per share and FY2027 from a loss of $1.17 to $1.46. Noble Financial estimates losses of $1.49 per share in 2026 and $2.14 in 2027, suggesting ongoing cash burn and weaker projected earnings. Greenwich LifeSciences analyst estimates
About Greenwich LifeSciences
Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.
Read More
- Five stocks we like better than Greenwich LifeSciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
